Oppenheimer raised the firm’s price target on Nyxoah to $17 from $12 and keeps an Outperform rating on the shares. The firm notes Nyxoah reported Q4 revenue of EUR 1.8M, in line with the pre-release and outpacing its/consensus original estimates of EUR 1.5M/EUR 1.4M. This represents an increase of 87% sequentially.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NYXH:
- Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
- Is NYXH a Buy, Before Earnings?
- Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- Nyxoah price target raised to $18 from $15 at H.C. Wainwright
- Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
